Would you re-test mazdutide after six weeks at 30 °C, or accept the original certificate?

Details up front: mazdutide · six weeks · 30 °C.

This is a planning question. I know what my options are; I do not know how to weigh them.

What I want is the minimum viable version, which I suspect is smaller than what I would design.

How do I make this decision on evidence rather than on feel?

To be exact about it, the single most misleading statement on a research-grade certificate is a lot number with no statement of how many vials from that lot were tested.

The sample size determination requires choosing a confidence level and an acceptable error rate, and the smaller the error rate you want, the larger your sample must be.

Under AQL sampling plans, testing two vials from a fifty-vial lot gives you an operating characteristic curve that tells you what risks you are accepting.

Assume segregation is possible, and design your sampling to catch it if it exists.

The underlying point is that the practical consequence is that spot-testing one vial from a new supplier is better than assuming they are all the same.

A statement that "lot 20260412 complies with specifications" is meaningless without stating which vials from the lot were tested and how many there were.

If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.

Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.

The caveat is that sampling is a trade-off between cost and confidence, and neither test nor assumption is cost-free.

If testing multiple vials, state how many you tested and why you chose those vials.

To be exact about it, thermal history during shipping is different for every vial, so a lot that experienced thermal abuse may have internal variation even if it was originally homogeneous.

Testing a vial that has been open in the lab for three months is testing aged material, not the fresh lot, and the result should be explicitly noted as a retest.

Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.

The limitation is that you cannot know for certain without testing every vial, and you almost never can afford to do that.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

edited 25 Mar 2025 by Dr_Yusuf_Adeyemi — fixed an arithmetic slip in the third paragraph

Specifically, start from the question: how many vials from this lot do I need to test to claim that the lot meets specification, and the answer depends on both the lot size and the acceptable risk.

If the entire lot failed qualification, a retest on a different vial is sometimes done, but reporting a retest result under the same lot number is misleading.

Worth noting that thermal excursions during shipping affect different vials differently, so the lot may not be homogeneous even if it left the factory that way.

Assume segregation is possible, and design your sampling to catch it if it exists.